Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0001062993-25-002549 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | 2025-02-12 | ENTA | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +25.5K | 872.1K | +3% | $0 | |
| 2025-02-14 | 2025-02-12 | ENTA | Luly Jay R. | Pres, CEO, Dir | F - Tax | $5.59 | -7,484 | 864.7K | -0.9% | -$41.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | A | A | 25,500 | $0.00 | 872,138 | D | — | — | (F1) Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025. |
| 2 | Common | Common Stock | 2025-02-12 | F | D | 7,484 | $5.59 | 864,654 | D | — | — | (F2) Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards. |